The Lift Line
Medicine that rewrites a patient’s genes cannot be regulated with a rulebook written for pills. India has just started rewriting the rulebook to match the science.
Why This Editorial Matters for Your Exam
The Drugs (Eighth Amendment) Rules, 2026, in force from June 29, 2026, sit at the intersection of science, regulation and bioethics, giving you a current anchor for questions on frontier technology and its governance.
GS Paper 3: Developments in biotechnology, indigenous innovation (India’s own CAR-T therapy), and the science-and-technology-in-health theme.
GS Paper 2: Regulation and the role of statutory and executive bodies (CDSCO, DCGI), and the governance challenge of balancing safety with innovation.
Prelims relevance: The Drugs and Cosmetics Act 1940 and Drugs Rules 1945, the Central License Approving Authority and CDSCO, NexCAR19, the BioE3 policy, and the biosafety bodies RCGM, GEAC and IBSC. These names are highly examinable.
Mains relevance: This is a model case for the ethics-of-emerging-technology theme (gene editing, xenotransplantation) and for the regulator’s dilemma of protecting patients without smothering a young industry.
Background and Context
Biotechnology has moved from treating disease to rewriting biology. Gene therapies can replace or edit faulty genes; cell and stem-cell therapies, including CAR-T therapy for blood cancers, reprogramme a patient’s own cells to fight disease; and xenografts use animal tissue in human medicine. India is a maker of these therapies too: NexCAR19, the country’s first indigenous CAR-T cell therapy, was approved by CDSCO in October 2023, developed by ImmunoACT out of a decade-long IIT Bombay and Tata Memorial Centre collaboration.
Until now, these advanced therapies lacked a clear, uniform national licensing route. The Drugs (Eighth Amendment) Rules, 2026, notified and in force from June 29, 2026, amend the Drugs Rules, 1945, to bring three categories, gene therapeutic products, cell and stem-cell-derived products (explicitly including CAR-T), and xenografts, under the Central License Approving Authority working with CDSCO. This ensures a single, central licensing standard rather than a patchwork of state approvals.
The wider policy backdrop is the BioE3 policy (Biotechnology for Economy, Environment and Employment), approved by the Cabinet in August 2024, which aims to make India a hub for high-value biomanufacturing across six themes, including precision biotherapeutics. India already prohibits germline gene therapy under its 2019 gene-therapy guidelines, keeping it to somatic (non-heritable) edits, and its 2017 stem-cell guidelines set up a national and institutional oversight structure.
The Core Argument / Issue
The central issue is the regulator’s balancing act: these therapies can cure previously untreatable diseases, but they carry novel and serious risks, so oversight must be strong enough for safety yet flexible enough not to kill a fledgling industry.
Why central licensing matters
Advanced therapies are complex, personalised and high-risk, so a fragmented, state-by-state approval regime invites inconsistency and unsafe products. Centralising approval under the CLAA and CDSCO gives one high, uniform bar for quality and safety, and it gives Indian innovators like ImmunoACT a clear, predictable path to market.
The ethics that regulation must encode
Frontier biotech forces hard ethical questions that the rules must answer.
| Technology | Promise | Ethical or safety risk |
|---|---|---|
| Gene therapy | Cure inherited disease | Off-target edits; germline editing must stay banned |
| CAR-T cell therapy | Treat blood cancers | Cytokine release syndrome; access and cost |
| Xenografts / xenotransplantation | Ease organ shortage | Cross-species infection risk; consent, dignity |
The global cautionary tale for gene editing is the He Jiankui affair of 2018, when a scientist created gene-edited babies and was widely condemned and jailed, which is why India, like most countries, bans heritable germline editing. Xenotransplantation, dramatised by the pig-heart transplant of January 2022 and a gene-edited pig-kidney transplant in 2024, carries the risk of animal viruses crossing into humans, demanding strict biosafety.
The innovation stake
Over-regulation can push Indian patients and companies abroad or delay life-saving therapies; under-regulation risks unsafe, unproven treatments marketed to desperate patients. The BioE3 vision of India as a biomanufacturing hub only works if regulation earns global trust while remaining efficient.
How to Think About This (Analytical Frame)
Use the precaution-versus-permission frame: for any powerful new technology, plot where a regulator should sit between two failure modes, being so cautious that it blocks beneficial innovation, and being so permissive that it exposes people to harm. The right position is not fixed; it is stricter where harm is irreversible (germline editing, cross-species infection) and lighter where harm is manageable and the benefit is large (a well-understood CAR-T therapy). This calibrated frame beats a blanket “regulate more” or “regulate less.”
The Diagram in Words
Frontier therapy (gene, cell, xenograft) -> novel and serious risks -> uniform central licensing via CLAA and CDSCO -> strict where harm is irreversible, flexible where benefit is large -> safe innovation and India as a trusted biomanufacturing hub
Way Forward
- Build specialised regulatory capacity. Train CDSCO reviewers in advanced-therapy science and create fast, risk-proportionate approval tracks for well-characterised therapies.
- Keep the ethical red lines bright. Maintain the ban on germline editing and enforce strict biosafety and consent norms for xenotransplantation.
- Coordinate the many regulators. Align CDSCO with the biosafety bodies (RCGM, GEAC, IBSC) and institutional ethics committees so innovators face one coherent system, not overlapping windows.
- Tackle access and cost. Support indigenous, affordable therapies like NexCAR19 so cutting-edge cures do not remain the preserve of the wealthy.
- Update rules continuously. Treat the framework as living, revising it as gene editing and xenotransplantation evolve.
PYQ Linkage and Practice
UPSC has asked about developments in biotechnology and their applications and ethical issues, and about gene-editing technologies such as CRISPR (biotech and genetic-engineering questions appear across recent years). This editorial adds the regulatory and ethical governance angle.
Practice question (Mains, GS3/GS2, 15 marks): “Regulating frontier biotechnology is an exercise in calibrated caution, not blanket control.” In the light of India’s new rules for gene therapy, CAR-T and xenografts, discuss how the state should balance patient safety with innovation. (250 words)
Sources: The Indian Express
Source: Editing the Rulebook: Regulating India's Frontier Biotech — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
